Top Markets
Coin of the day
Maxigen Biotech Inc. Maxigen Biotech Inc.

Maxigen Biotech Inc.

1783
株式のランク #21088
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development,... Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
株価
$1.28
最終同期: 2026-08-21
時価総額
$115.23M
変化(1日)
-0.25%
変化(1年)
-10.17%
TW
取引 Maxigen Biotech Inc. (1783)

カテゴリー

Maxigen Biotech Inc.(1783)の利益
2026 時点の利益 TTM: 0
Maxigen Biotech Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Maxigen Biotech Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益